ATB 0,+ transporter-mediated targeting delivery to human lung cancer cells via aspartate-modified docetaxel-loading stealth liposomes
Source abstract
Abstract
Tumor cells have an increased demand for amino acids to support their rapid growth and malignant metastasis. Transfer of amino acids across plasma membranes depends on several amino acid transporters that are highly upregulated in tumor cells and are promising targets for tumor cell-selective therapy. In this study, stealth liposomal systems functionalized with aspartate-polyoxyethylene stearate conjugate (APS) were developed for transporter-mediated targeted delivery to ATB0,+, which is overexpressed human lung cells. The resultant ATB0,+-targeting liposomes (APS-Lips) consisted of a liposome core and the surface coverage of the APS modifier had an optimized density of 10%. APS-Lips had a uniform particle size distribution and high encapsulation efficiency of docetaxel (DTX, >80%). APS modification had a negligible effect on the DTX release from liposomes. Compared with Taxotere and unmodified liposomes, APS-Lips showed increased intracellular delivery and antitumor potency against human lung cells. Furthermore, competitive endocytosis studies showed that the cellular uptake of APS-Lips was notably decreased in the presence of glycine, a typical substrate of ATB0,+, and was increased through adhesion to the cell membrane via transporter-substrate interactions. Finally, in vitro hemolysis and in vivo vascular irritation studies in rabbits confirmed the good blood compatibility and minimal vascular stimulation of the synthetic ATB0,+-targeting material APS. These results demonstrated that the aspartate-modified liposomes could be a promising nanocarrier for ATB0,+ transporter-mediated targeted drug delivery to treat lung cancer.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy
Shenyang Pharmaceutical University
Shenyang 110016
China
Department of Pharmacy
College of life science and biological pharmacy
Department of Biomedical Engineering
School of Medical Devices
Shenyang
Municipal Key Laboratory of Biopharmaceutics
References (20)
Show source-provided references
1. Papademetriou · J. Controlled Release · 2014 · 188 · 8710.1016/j.jconrel.2014.06.008 ↗
2. Muro · J. Controlled Release · 2012 · 164 · 12510.1016/j.jconrel.2012.05.052 ↗
3. Danhier · J. Controlled Release · 2010 · 148 · 13510.1016/j.jconrel.2010.08.027 ↗
4. B. R. Stevens , in Epithelial Transport Physiology, ed. G. A. Gerencser, Humana Press, Totowa, NJ, 2010, pp. 353–378, 10.1007/978-1-60327-229-2_1510.1007/978-1-60327-229-2_15 ↗
5. Rivenzon-Segal · Am. J. Physiol.: Endocrinol. Metab. · 2000 · 279 · E508
6. Harris · Proc. Natl. Acad. Sci. U. S. A. · 2009 · 106 · 1813110.1073/pnas.0909049106 ↗
7. Marshman · Biochem. Pharmacol. · 2001 · 61 · 47710.1016/S0006-2952(00)00574-8 ↗
8. Okabe · Mol. Cancer Ther. · 2008 · 7 · 308110.1158/1535-7163.MCT-08-0539 ↗
9. Gupta · Biochim. Biophys. Acta · 2005 · 1741 · 21510.1016/j.bbadis.2005.04.002 ↗
10. Kwak · Xenobiotica · 2012 · 42 · 60310.3109/00498254.2011.646339 ↗
11. Ganapathy · Curr. Drug Targets: Immune, Endocr. Metab. Disord. · 2005 · 5 · 35710.2174/1568009054629681 ↗
12. Gullotti · Mol. Pharm. · 2009 · 6 · 104110.1021/mp900090z ↗
13. Gao · Nano Lett. · 2002 · 2 · 97910.1021/nl025604a ↗
14. Fontana · Biomaterials · 2001 · 22 · 285710.1016/S0142-9612(01)00030-8 ↗
15. Elias · Nanomedicine: Nanotechnol. Biol. Med. · 2013 · 9 · 19410.1016/j.nano.2012.05.015 ↗
16. Sloan · J. Biol. Chem. · 1999 · 274 · 2374010.1074/jbc.274.34.23740 ↗
17. Karunakaran · Biochem. J. · 2008 · 414 · 34310.1042/BJ20080622 ↗
18. Bunjes · J. Pharm. Pharmacol. · 2010 · 62 · 163710.1111/j.2042-7158.2010.01024.x ↗
19. Zhou · Mol. Pharm. · 2013 · 10 · 383210.1021/mp400303w ↗
20. Xiong · Int. J. Pharm. · 2011 · 421 · 27510.1016/j.ijpharm.2011.10.008 ↗